Monkeypox outbreak in the Netherlands in 2022: public health response, epidemiological and clinical characteristics of the first 1000 cases and protection of the first-generation smallpox vaccine

  1. Catharina E. van Ewijk
  2. Fuminari Miura
  3. Gini van Rijckevorsel
  4. Henry J.C. de Vries
  5. Matthijs R.A. Welkers
  6. Oda E. van den Berg
  7. Ingrid H.M. Friesema
  8. Patrick van den Berg
  9. Thomas Dalhuisen
  10. Jacco Wallinga
  11. Diederik Brandwagt
  12. Brigitte A.G.L. van Cleef
  13. Harry Vennema
  14. Bettie Voordouw
  15. Marion Koopmans
  16. Annemiek A. van der Eijk
  17. Corien M. Swaan
  18. Margreet J.M. te Wierik
  19. Tjalling Leenstra
  20. Eline Op de Coul
  21. Eelco Franz
  22. the Dutch Monkeypox Response Team

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

In early May 2022 a global outbreak of monkeypox (MPX) started among persons without a travel history to regions known to be enzootic for monkeypox-virus. On August 8 2022, the Netherlands reported its 1000 th monkeypox case representing a cumulative incidence of 55 per million population, one of the highest cumulative incidences worldwide. Here we describe the epidemiological characteristics and clinical presentation of the first 1000 monkeypox cases in the Netherlands, within the context of the public health response. Additionally, we explored risk factors for and estimated the protective effect of first-generation smallpox vaccine against more severe MPX.

The first 1000 MPX cases, reported between May 20 and August 8 2022, were predominantly MSM aged 31-45 years. The vast majority of infections were acquired through sexual contact with casual partners in private or recreational settings including LGBTQIA+ venues in the Netherlands. This indicates that, although some larger upsurges occurred from point-source and/or travel related events, the outbreak is mainly characterised by sustained transmission within the Netherlands. More severe MPX was associated with having one or more comorbidities as well as having participated in more (3+) different sexual activities 21 days before symptom onset. We found a vaccine effectiveness of the prior first-generation smallpox vaccine against more severe MPX of 58% (95% CI 17-78%), suggesting moderate protection against more severe MPX symptoms on top of any possible protection by this vaccine against MPXV infection and disease.

Article activity feed

  3. Version published to 10.1101/2022.10.20.22281284v1 on medRxiv